Recruitment completed in Traumakine INTEREST Trial
(WorldNews Finland)

Faron Pharmaceuticals Ltd (`Faron` or the `Company`) Recruitment completed in Traumakine INTEREST Trial The upcoming read-out will collate intact 90 day morbidity/mortality data alongside 28 day mortality data as requested by the study IDMC Phase III INTEREST top line results expected in H1 2018 TURKU - FINLAND, 11 December 2017 - Faron Pharmaceuticals Ltd (`Faron`) (AIM: FARN), the clinical stage biopharmaceutical company, announces that it has completed recruitment, on track, for its Phase III INTEREST trial of Traumakine for the treatment of moderate to severe Acute Respiratory Distress Syndrome (ARDS). In addition to the completion of recruitment, the Company reports that it has adopted...